Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Abstract Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress. We here show that glutamyl-prolyl-tRNA synthetase (GluProRS) inhibition constitutes a novel therapeutic target. Genomic dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Keiji Kurata, Anna-James Bott, Mark A. Tye, Leona Yamamoto, Mehmet K. Samur, Yu-Tzu Tai, James Dunford, Catrine Johansson, Filiz Senbabaoglu, Martin Philpott, Charlotte Palmer, Karthik Ramasamy, Sarah Gooding, Mihaela Smilova, Giorgia Gaeta, Manman Guo, John C. Christianson, N. Connor Payne, Kritika Singh, Kubra Karagoz, Matthew E. Stokes, Maria Ortiz, Patrick Hagner, Anjan Thakurta, Adam Cribbs, Ralph Mazitschek, Teru Hideshima, Kenneth C. Anderson, Udo Oppermann
Formato: Artículo
Lenguaje:English
Publicado: Nature Publishing Group 2023-01-01
Colección:Blood Cancer Journal
Acceso en línea:https://doi.org/10.1038/s41408-023-00787-w

Internet

https://doi.org/10.1038/s41408-023-00787-w

Ejemplares similares